Lawyers USA Your Business Partner

Dilantin lawsuits turn into a mini mass tort 

By: Sylvia Hsieh
Published: February 7, 2011

Tags: Dilantin, drug litigation, epilepsy, FDA, Food and Drug Administration, Mylan, off-label uses, Pfizer, phenytoin, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis

Litigation over the anti-seizure drug Dilantin has developed into a smaller-scale mass tort, with dozens of suits claiming that it causes horrendous and life-threatening skin burns.

Pfizer to pay $142.1 million over marketing of epilepsy drug 

By: Tony Ogden
Published: January 31, 2011

Tags: marketing, Neurontin, Pfizer, racketeering

Pfizer, the drug maker, has been ordered to pay a total of $142.1 million in damages for violating federal racketeering laws in the marketing of its epilepsy drug Neurontin.

Drug litigation in review 2010 

By: Tony Ogden
Published: January 4, 2011

Tags: Accutane, Allergan, antidepressant, Avandia, AztraZeneca, Botox, Botox litigation, Department of Justice, DOJ, epilepsy, failure to warn, GlaxoSmithKline, heart attack, hormone replacement therapy, hormone replacement therapy litigation, Johnson & Johnson, Levaquin, Neurontin, Paxil, Pfizer, Premarin, Prempro, Provera, Roche, Seroquel, Wyeth

Much like 2009, 2010 was a busy year for prescription drug suits.

Pfizer ordered to pay $1.5 million in Prempro damages 

By: Tony Ogden
Published: January 3, 2011

Tags: breast cancer, Pfizer, Prempro, Puerto Rico

Pfizer Inc. must pay $1.5 million in damages to a pharmacist who developed breast cancer after taking one of the company’s menopause drugs, a jury in Puerto Rico has ruled.

U.S. Trustee advises dismissal of Pfizer unit’s bankruptcy 

By: Tony Ogden
Published: December 28, 2010

Tags: asbestos, Bankruptcy, Pfizer

Pfizer Inc. should have the bankruptcy of its Quigley unit dismissed, lawyers for the U.S. Trustee said.

While the bankruptcy has been pending, creditors with alleged asbestos-related health problems have been unable to sue New York-based Pfizer, and many have died, wrote lawyers for the U.S. Trustee, an arm of the Justice Department that oversees bankruptcy. A hearing to decide the U.S. Trustee’s request is set for Jan. 13, according to court papers filed Dec. 23.

Study: HRT drug boosts risk of cancer death 

By: Kimberly Atkins
Published: October 21, 2010

Tags: breast cancer, drug litigation, failure to warn, hormone replacement therapy, Pfizer, Prempro, Wyeth

Post-menopausal women who take a popular hormone drug combination therapy are at increased risk of getting breast cancer as well as dying from the disease, according to a new federal study.

HRT litigation rolls on 

By: Nora Tooher
Published: August 31, 2010

Tags: hormone replacement therapy litigation, Pfizer, Premarin, Prempro, Provera, Upjohn, Wyeth

With Pfizer and plaintiffs’ lawyers squabbling over who has won the most hormone replacement therapy trials, only one thing about the litigation is clear: it’s turning into one of the longest-running mass torts in U.S. history.

Pfizer settles Prempro case before damages retrial 

By: Tony Ogden
Published: August 30, 2010

Tags: Arkansas, breast cancer, Pfizer, Prempro

Pfizer Inc. has agreed to settle an Arkansas woman’s claims that the company’s Prempro menopause drug caused her breast cancer before the drugmaker endured another trial over punitive damages in the case, according to a court filing.

Pfizer settles Neurontin wrongful death suit 

By: Nora Tooher
Published: May 18, 2010

Tags: Neurontin, off-label uses, Pfizer, wrongful death

A settlement has been reached in the third Neurontin wrongful death case, which was scheduled to begin trial Tuesday in U.S. District Court in Nashville, Tenn.

New trial in hormone replacement therapy case 

By: Correy Stephenson
Published: May 11, 2010

Tags: drug litigation, hormone replacement therapy, Pfizer, Provera

Pfizer is entitled to a new trial in a hormone replacement therapy drug suit, a trial court judge in Pennsylvania has ruled.